We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-7.77%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$150M
AUM Growth
-$15.8M
Cap. Flow
+$2.4M
Cap. Flow %
1.6%
Top 10 Hldgs %
78.1%
Holding
51
New
–
Increased
6
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
QDEL icon
QuidelOrtho
QDEL
+$1.72M
2
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$1.43M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$389K
4
ALBO
Albireo Pharma Inc
ALBO
+$291K
5
AMRN
Amarin Corp
AMRN
+$240K

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$769K
2
AWH
Aspira Women's Health Inc. Common Stock
AWH
+$709K
3
NARI
Inari Medical, Inc. Common Stock
NARI
+$193K
4
WKHS icon
Workhorse Group
WKHS
+$114K

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Energy 1.16%
3 Consumer Discretionary 0.13%
4 Consumer Staples 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VNDA icon
26
Vanda Pharmaceuticals
VNDA
$312M
$773K 0.52%
80,000
– –
IMGN
27
DELISTED
Immunogen Inc
IMGN
$684K 0.46%
190,000
– –
STOK icon
28
Stoke Therapeutics
STOK
$1.82B
$670K 0.45%
20,000
– –
BHVN
29
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$650K 0.43%
10,000
– –
FOLD
30
DELISTED
Amicus Therapeutics
FOLD
$537K 0.36%
38,000
– –
NARI
31
DELISTED
Inari Medical, Inc. Common Stock
NARI
$483K 0.32%
7,000
-3,000
-30% -$193K
XNCR icon
32
Xencor
XNCR
$1.44B
$477K 0.32%
12,300
– –
CLR
33
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$474K 0.32%
38,600
– –
GTHX
34
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$462K 0.31%
40,000
– –
PGNY icon
35
Progyny
PGNY
$2.44B
$441K 0.29%
15,000
– –
TBIO
36
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$408K 0.27%
30,000
– –
TGTX icon
37
TG Therapeutics
TGTX
$8.58B
$401K 0.27%
15,000
– –
KALV
38
DELISTED
KalVista Pharmaceuticals
KALV
$378K 0.25%
30,000
– –
ARVN icon
39
Arvinas
ARVN
$518M
$354K 0.24%
15,000
– –
ICPT
40
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$344K 0.23%
8,300
– –
PXD
41
DELISTED
Pioneer Natural Resource Co.
PXD
$327K 0.22%
3,800
– –
VYGR icon
42
Voyager Therapeutics
VYGR
$187M
$320K 0.21%
30,000
– –
IFRX icon
43
InflaRx
IFRX
$256M
$298K 0.2%
70,000
– –
OVV icon
44
Ovintiv
OVV
$17.5B
$280K 0.19%
34,350
– –
ODT
45
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$269K 0.18%
20,000
– –
APLS
46
DELISTED
Apellis Pharmaceuticals
APLS
$241K 0.16%
8,000
– –
WKHS icon
47
Workhorse Group
WKHS
$29.5M
$202K 0.14%
3
-2
-40% -$114K
DRNA
48
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$180K 0.12%
10,000
– –
YTEN
49
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$147K 0.1%
790
– –
BCRX icon
50
BioCryst Pharmaceuticals
BCRX
$2.37B
$69K 0.05%
20,000
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
AF
Align Financial Hermantown, Minnesota $176M AUM
OA
Oceanside Advisors Mount Pleasant, South Carolina $175M AUM 17.96% 1-Year Est. Return

Birchview Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Birchview Capital held 51 positions worth $150M, down 9.5% from $165M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Trading was light in Q3 2020: portfolio turnover was 2%. Birchview Capital opened no new positions and exited 1, leaving the 51-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Discretionary.

  • Birchview Capital added most to QuidelOrtho in Q3 2020, an estimated $1.72M increase.
  • Birchview Capital's biggest Q3 2020 reduction was Aspira Women's Health Inc. Common Stock, cutting an estimated $709K.
  • Birchview Capital fully exited Gilead Sciences in Q3 2020, selling an estimated $769K.
  • Birchview Capital's ten largest holdings make up 78% of its $150M portfolio in Q3 2020.
  • Birchview Capital opened 0 new positions and closed 1 in Q3 2020.
  • Birchview Capital's portfolio value fell 9.5% quarter-over-quarter to $150M.

Based on Birchview Capital's 13F filing for Q3 2020, filed 12 Nov 2020.